At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 180 enrolled
Drug / intervention
Hyperbaric Levobupivacaine 0.75%drug
Likely dose
Hyperbaric Levobupivacaine 0.75% 4 mlfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Spinal Anesthesia With Hyperbaric Levobupivacaine 0.75% for Ambulatory Knee Arthroscopy: A Double Blind, Randomized Clinical Trial Comparing Three Low Doses
In Brief
A Phase 4 clinical trial evaluating Hyperbaric Levobupivacaine 0.75% for Disorder of Knee and Anesthesia. Completed, enrolled 180 participants across 1 site.
Detailed Summary
The purpose of this study is to evaluate motor block probability throughout time and clinical profile when using three different doses of HLBP 0.75% (7.5, 9.37 and 11.25 mg) by a unilateral spinal block technique.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDisorder of Knee, Anesthesia
CountriesColombia
Collaborators--
Timeline
Phase 4CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJun 2006
Primary CompletionDec 2009
Study CompletionJul 2010
First PostedJun 2013
TodayJul 2026
First PostedJun 19, 2013
Enrollment StartJun 1, 2006
Primary CompletionDec 1, 2009
Study CompletionJul 1, 2010
TodayJul 2, 2026
Enrollment to primary: 3.5 yearsPosted 13.0 years ago
Interventions
Hyperbaric Levobupivacaine 0.75%drug
Each 4 ml of the administred solution contains: Chlorhydrate Levogyre Bupivacaine 30 mg, Glucose 290.8 mg and water for injection c.s.